Table 3.
Comparison of HTP and conventional cigarette users (dual users) vs HTP exclusive users (single users) at 12-, 24- and 36-month follow-up visits
| Parameter | Baseline | 12-Month follow-up | p valuec | 24-Month follow-up | p valuec | 36-Month follow-up | p valuec |
|---|---|---|---|---|---|---|---|
| COPD HTP users reducing cig use (dual users) | (n = 8) | (n = 8) | (n = 7) | (n = 6) | |||
| Sex | 7M, 1F | 7M, 1F | 7M | 6M | |||
| % Smoking reduction from baseline | – | 82 (± 5.7) % | – | 83.9 (± 6.2) % | – | 81.8 (± 5.9) % | – |
| Post-BD FEV1a (L) | 1.27 (0.97, 1.88) | 1.37 (0.99, 2.01) | 0.024 | 1.85 (0.99, 2.13) | 0.063 | 1.53 (0.99, 1.97) | 0.686 |
| Post-BD FVCa (L) | 2.47 (2.03, 3.05) | 2.58 (2.13, 3.1) | 0.050 | 2.91 (2.37, 3.12) | 0.176 | 2.84 (2.35, 3.12) | 1.000 |
| %FEV/FVCb | 56.1 (± 9.1) | 55.9 (± 10.3) | 0.980 | 57 (± 12.1) | 0.863 | 53.7 (± 10.8) | 0.873 |
| Cig/dayb | 21 (± 4.6) | 3.6 (± 1.1) | < 0.001 | 3.3 (± 1.3) | < 0.001 | 3.7 (± 1) | < 0.001 |
| CAT scorea | 23 (18.3, 26) | 20 (16, 21) | 0.018 | 18 (13.5, 21) | 0.027 | 19 (13.5, 23.8) | 0.027 |
| COPD exacerbationsb | 2.1 (± 0.6) | 1.6 (± 0.5) | 0.108 | 1.1 (± 0.7) | 0.077 | 1.2 (± 0.4) | 0.021 |
| Parameter | Baseline | 12-Month follow-up | p valuec | 24-Month follow-up | p valuec | 36-Month follow-up | p valuec |
|---|---|---|---|---|---|---|---|
| COPD HTP users ceasing cig use (single users) | (n = 11) | (n = 11) | (n = 12) | (n = 13) | |||
| Sex | 8M, 3F | 8M, 3F | 8M, 4F | 9M, 4F | |||
| % Smoking reduction from baseline | – | 100% | – | 100% | – | 100% | – |
| Post-BD FEV1a (L) | 1.38 (1.03, 1.71) | 1.26 (1.02, 1.75) | 0.722 | 1.35 (1.17, 1.64) | 0.504 | 1.3 (1.1, 1.65) | 0.401 |
| Post-BD FVCa (L) | 2.6 (2.19, 2.67) | 2.6 (2.7, 2.73) | 0.689 | 2.44 (1.83, 2.83) | 0.814 | 2.5 (1.8, 2.78) | 0.727 |
| %FEV/FVCb | 58.1 (± 11) | 58 (± 11) | 0.991 | 58.7 (± 9.2) | 0.675 | 59 (± 10) | 0.881 |
| Cig/dayb | 20.2 (± 2.3) | – | – | – | |||
| CAT scorea | 18 (17, 23) | 15 (14, 17) | 0.004 | 16 (14.8, 18) | 0.003 | 15 (14, 20) | 0.036 |
| COPD Exacerbationsb | 2.1 (± 1) | 1.2 (± 1) | 0.048 | 1.3 (± 0.9) | 0.021 | 1.3 (± 1) | 0.035 |
Significant differences are noted in bold
Bolditalic indicates significant comparison
COPD chronic obstructive pulmonary disease, HTP heated tobacco product, n number, BD bronchodilator, L litre, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, Cig conventional cigarettes, CAT COPD assessment tool, 6MWD 6-minute walk distance, m metres
aMedian (interquartile range)
bMean (± standard deviation)
cWithin-group p value vs baseline